Portal de Periódicos da CAPES

Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients

2003; Thieme Medical Publishers (Germany); Linguagem: Inglês

10.1160/th-02-11-0264

2567-689X

Maxime P. Look, Wim van Putten, Michael Duffy, Nadia Harbeck, Ib Jarle Christensen, Christoph Thomssen, Ronald Kates, Frédérique Spyratos, Mårten Fernö, Serenella Eppenberger‐Castori, Fred C.G.J. Sweep, Kurt Ulm, Jean‐Philippe Peyrat, Pierre‐Marie Martin, H Magdelénat, Nils Brünner, Catherine Duggan, Björn W Lisboa, Pär‐Ola Bendahl, Véronique Quillien, A Daver, Gabriel Ricolleau, Marion Meijer-van Gelder, Peggy Manders, W. Edward Fiets, Marinus A. Blankenstein, Philippe Broët, Sylvie Romain, G. Daxenbichler, Gudrun Windbichler, Tanja Čufer, Simona Borštnar, Willy Kueng, L.V.A.M. Beex, Jan G.M. Klijn, N. J. O’Higgins, Urs Eppenberger, F. Jänicke, Manfred Schmitt, John A. Foekens, Pär-Ola Bendah,

Peptidase Inhibition and Analysis

In this report we present an extension of the pooled analysis of the prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I in breast cancer patients. We analyzed a different endpoint, metastasis-free survival (MFS). We checked the consistency of the estimates for uPA and PAI-1 for relapse-free survival (RFS) and MFS exploring possible sources of heterogeneity. Nodal status, the most important prognostic factor for breast cancer, introduced heterogeneity in the uPA/PAI-1 survival analyses, reflecting the interaction between nodal status and uPA/PAI-1. The estimates for uPA and PAI-1 were found to be consistent, even when a different transformation of their values was used. The heterogeneity of the separate data sets decreased if the levels of uPA and PAI-1 were ranked, data sets were pooled, and the analyses corrected for the base model that included all traditional prognostic factors, and stratified by data set. We conclude that uPA and PAI-1 are ready to be used in the clinic to help classify breast cancer patients into high and low risk groups.